Thermo Fisher Bioproduction Insights

  1. How Can Bioprocessing Professionals Evolve Their Manufacturing For Greater Flexibility And Efficiency? 4/21/2026

    Manufacturing flexibility is now a competitive differentiator. Here's how single-use technologies are reshaping bioprocessing facility design, scalability, and sustainability strategy.

  2. 3 Innovations For Reducing Risk In Continuous Downstream Bioprocessing 4/21/2026

    Batch-to-continuous transitions in downstream bioprocessing carry real risks. Here's how advanced analytics, smarter buffer strategies, and single-use systems are changing that calculus.

  3. Criteria For Effective Bioprocess Scale-Up 3/25/2026

    Discover four essential bioprocess scale-up criteria and how each balances hydrodynamics, shear, and mass transfer across manufacturing scales.

  4. Demonstrating Bioprocess Scalability Through Platform Consistency 3/25/2026

    Explore how a unified bioreactor design enables consistent process performance from bench to production, minimizing scale-up risk while maintaining cell growth and yield.

  5. Titer Analysis In The Era Of Complex Antibody Therapeutics 3/13/2026

    As antibody formats grow more complex, titer is harder to measure. Chromatography cuts through matrix noise to deliver accurate, scalable quantification from early development through QC.

  6. The Future Of RNA Manufacturing Starts With Raw Material Innovation 2/11/2026

    Amid the mRNA and oligonucleotide therapeutic boom, sponsors and manufacturers are exploring how to make critical raw materials—capping agents, lipid nanoparticles, and RNA polymerase—more effective.

  7. Reframing Residual DNA Testing: What It Is--And What It Isn't 2/11/2026

    Residual host-cell DNA quantitation requires sensitive, well-validated analytical workflows to ensure accurate impurity control, process understanding, and regulatory compliance in complex biologics.

  8. Activate Advanced Contamination Control Technology To Safeguard Your Cell Therapy 2/6/2026

    The most common contamination risks in cell therapy manufacturing are open processes that leverage different products, inflexible instruments, labor intensive workflows, lack of in-line monitoring, and zero failure tolerance.

  9. Integrated Upstream And Downstream Strategies For Robust Manufacturing 2/5/2026

    Process robust mAb production requires understanding scale dependent cell environments, leveraging predictive models, and pursuing data driven control to minimize variability and optimize quality.

  10. Multispecific Antibodies: Key Challenges And Solutions To Enable A New Frontier In Cancer Treatment 11/14/2025

    Multispecific antibodies are a newer class of cancer therapeutics addressing tumor complexity. Learn about the design, manufacturing, and regulatory challenges and integrated solutions accelerating their development.